Sixty-eight percent of patients with moderate-to-severe plaque psoriasis achieved PASI 90 at Week 24 in the ONWARD1 trial — a number that lands meaningfully above the roughly 50–55% PASI 90 benchmarks typically seen in late-stage oral TYK2 inhibitor programs. That single figure is the clinical argument Alumis is betting its NDA on, and the Phase 3 data presented at AAD make clear the company intends to position envudeucitinib not as a me-too deucravacitinib competitor but as a step-change in what allosteric TYK2 inhibition can deliver orally.
The response kinetics deserve scrutiny. Quality-of-life improvements and itch relief preceded PASI 90 clearance — a sequencing that matters clinically because patient-reported outcomes arriving early tend to drive real-world adherence and physician confidence. More telling still, over 30% of patients hit clear or almost-clear scalp by Week 4, a region notorious for poor response to oral agents. That early scalp signal, combined with sustained PASI 100 rates of 41% and 39.5% across the two trials at Week 24, gives Alumis a differentiation story rooted in body-site-specific data rather than aggregate endpoint arithmetic. The safety profile tracking consistent with Phase 2 removes the primary obstacle that could have complicated the NDA package.
The LUMUS Phase 2b readout in SLE, expected in Q3 2026, is the trial that actually determines whether envudeucitinib becomes a franchise or a single-indication drug. SLE is a notoriously difficult efficacy environment — the graveyard of biologics and small molecules alike — and a Phase 2b miss there would compress the asset’s commercial ceiling sharply, regardless of what the psoriasis approval delivers. Alumis carries $569.5 million in cash against a $93.1 million quarterly burn, giving it runway into Q4 2027. That clock is tight but not catastrophic assuming the NDA files on schedule and no major additional indication spend is triggered before a first approval.
The one number worth tracking from here is the PASI 100 rate at the Week 52 ONWARD3 long-term readout due in the second half of 2026: durable complete clearance at one year is what separates a strong oral therapy from a category-defining one, and the NDA reviewer will weigh it heavily against deucravacitinib’s long-term data already in the public domain.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
